Cancer News and Research

Latest Cancer News and Research

Study explains why some cancer vaccines are not as effective as hoped

A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.

31 Aug 2012

Lance Armstrong Foundation, SmartBrief launch new weekly digital media news service

SmartBrief, Inc. launched a weekly digital media news service today in partnership with the Lance Armstrong Foundation.

31 Aug 2012

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Weill Cornell Medical College has been awarded three new research grants from the Leukemia & Lymphoma Society totaling $1.8 million. The funds will support critically-needed translational research for blood cancers, accelerating promising discoveries from the laboratory to the patient's bedside.

31 Aug 2012

Study confirms link between hormone replacement therapy use and breast cancer

The Million Women Study is a study, conducted by UK researchers, of women's health analyzing data from more than one million women aged 50 and over. It is a collaborative project between Cancer Research UK and the National Health Service (NHS), with additional funding from the Medical Research Council (UK).

31 Aug 2012

Impulsive and compulsive personality traits linked with traumatic upbringing during childhood

Previous research has shown that personality traits such as impulsivity or compulsiveness are indicators of an increased risk of addiction. Now, new research from the University of Cambridge suggests that these impulsive and compulsive personality traits are also associated with a traumatic upbringing during childhood.

31 Aug 2012

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Soligenix, Inc., a development stage biopharmaceutical company, announced today the results of a Phase 1B clinical trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax, designed to improve the immunogenicity of the vaccine.

31 Aug 2012

Researchers discover new immune response mechanism during infection

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a new "first response" mechanism that the immune system uses to respond to infection. The findings challenge the current understanding of immunity and could lead to new strategies for boosting effectiveness of all vaccines. The study, conducted in mice, published online today in the journal Immunity.

31 Aug 2012

Studies examine how PML gene regulates the fatty acid oxidation pathway

Two papers led by scientific teams from the Cancer Genetics Program at Beth Israel Deaconess Medical Center (BIDMC) shed new light on the genetic mechanisms underlying cellular energy and metabolism and, at the same time, highlight both the challenges and opportunities of genetic approaches to cancer treatment.

31 Aug 2012

MidCap, EpiCept amend Loan and Security Agreement

EpiCept Corporation announced today that it has amended the Company's Loan and Security Agreement with MidCap Financial, LLC effective August 27, 2012.

31 Aug 2012

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.

31 Aug 2012

U.S. lags three other industrialized nations in potentially preventable death rates

The United States lags three other industrialized nations-France, Germany, and the United Kingdom-in its potentially preventable death rate, and in the pace of improvement in preventing deaths that could have been avoided with timely and effective health care, according to a Commonwealth Fund-supported study published as a web first online today in Health Affairs.

31 Aug 2012

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.

31 Aug 2012

Researchers discover how tamoxifen-resistant breast-cancer cells grow and proliferate

A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.

31 Aug 2012

Quest Diagnostics announces availability of TERC test for cervical cancer

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory test that identifies molecular changes to cervical cells that increase the likelihood a woman may develop cervical cancer.

From Quest Diagnostics 31 Aug 2012

PD0325901 drug may hold potential to prevent neurofibromatosis 1 in children

A drug originally developed to stop cancerous tumors may hold the potential to prevent abnormal brain cell growth and learning disabilities in some children, if they can be diagnosed early enough, a new animal study suggests.

31 Aug 2012

Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors

Arrowhead Research Corporation, a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of CALAA-01, its RNAi therapeutic candidate targeting solid tumors. All patients participating in the trial have completed dosing with the exception of one patient who is still receiving treatment and will continue to be monitored.

31 Aug 2012

Cancer News and Research

Latest Cancer News and Research

Study explains why some cancer vaccines are not as effective as hoped

Lance Armstrong Foundation, SmartBrief launch new weekly digital media news service

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Study confirms link between hormone replacement therapy use and breast cancer

Impulsive and compulsive personality traits linked with traumatic upbringing during childhood

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Researchers discover new immune response mechanism during infection

Studies examine how PML gene regulates the fatty acid oxidation pathway

MidCap, EpiCept amend Loan and Security Agreement

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

U.S. lags three other industrialized nations in potentially preventable death rates

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Researchers discover how tamoxifen-resistant breast-cancer cells grow and proliferate

Quest Diagnostics announces availability of TERC test for cervical cancer

PD0325901 drug may hold potential to prevent neurofibromatosis 1 in children

Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors

Roundup: Brown's pension plan no panacea for Calif.; Personhood amendment won't make Colo. ballot

Emergency readmission after endoscopy linked to mortality risk

Oral lesion progression markers validated, discovered

Sterotactic radiotherapy offers good results in recurrent head and neck cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in